Cornerstone Therapeutics, a specialty pharma in Cary, has acquired a small Philadelphia pharma that recently filed a new drug application with the FDA.

Cornerstone will acquire all outstanding shares of Cardiokine but financial terms of the deal were not disclosed.

Under CEO Craig Collard, Cornerstone has focused on acquiring and developing drugs used by hospitals. Cardiokine, which develops cardiovascular products for hospitals, fits in with that strategy.